Tailored therapy boosts hope for older leukemia patients
NCT ID NCT03226418
First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tested a personalized approach to treating acute myeloid leukemia (AML) in adults aged 60 and older. Instead of a one-size-fits-all plan, doctors used genetic tests and a health assessment to choose either standard intensive chemo or a gentler therapy. The goal was to see if this tailored strategy could improve remission rates and survival while reducing side effects. The study involved 75 participants and tracked their health for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.